Target Hospitals NeuraSignal offers a fully reimbursable NG2 system for real-time cerebral blood flow assessment that can be adopted by hospitals, stroke centers, ASCs, and rural clinics, presenting a clear upsell path to diverse care settings seeking improved stroke prevention capabilities.

STROKE prevention The platform automates transcranial Doppler exams to detect right-to-left shunts, emboli, and cerebral vasospasm, enabling clinicians to act earlier and reduce second-stroke risk, a compelling value proposition for single-visit and ongoing monitoring contracts.

AI and Robotics NG2 leverages AI and robotics to deliver hands-free, autonomous TCD exams, highlighting opportunities for training, integration with existing imaging workflows, and potential partnerships with hospital IT and stroke teams to streamline adoption.

Expansion potential With a mid-size team and substantial funding, NeuraSignal is positioned to scale sales efforts into mid-sized and rural health networks, leveraging the 30% cryptogenic stroke insight to justify protocol changes and purchasing decisions.

Competitive edge NG2’s ability to detect three times more PFOs than standard echo and identify more treatable shunts provides a differentiator in the neurovascular imaging market, enabling sales pitches focused on diagnostic accuracy, faster care, and reimbursement-ready workflows.